Does inhibition of PKCα/β with ruboxistaurin antagonize heart failure in pigs after myocardial infarction injury?
These results provide additional evidence in a large animal model of disease that PKCα/β inhibition (with ruboxistaurin) represents a tenable and novel therapeutic approach for treating human heart failure.
Punch biopsy does not reduce the occurrence of negative histology after large loop excision of the transformation zone.